By a News Reporter-Staff News Editor at Biotech Week -- Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced its financial results for the quarter ended June 30, 2014 (see also Anacor Pharmaceuticals, Inc.).
"2014 has been a significant year for Anacor," said Paul Berns, President and Chief Executive Officer of Anacor Pharmaceuticals. "The FDA approved our New Drug Application for KERYDINTM to treat onychomycosis of the toenails, and we signed a strategically and financially significant agreement with Sandoz to commercialize KERYDIN in the United States through PharmaDerm, Sandoz's branded dermatology division. In addition, we initiated our pivotal Phase 3 studies of AN2728 to treat mild-to-moderate atopic dermatitis, and are pleased with the current pace of enrollment, which we believe keeps us on track to report top-line data in the second half of 2015." Recent Highlights and Developments On July 8, 2014, we announced that the U.S. Food and Drug Administration approved our New Drug Application for KERYDIN (tavaborole) topical solution, 5%. KERYDIN is the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today.
On July 21, 2014, we announced that we had entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize KERYDIN in the United States. PharmaDerm, the branded dermatology business of Sandoz, will be responsible for the sales and marketing of KERYDIN.
Our lead product candidate is AN2728, an investigational anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch. According to the National Eczema Association, almost 18 million people in the United States have atopic dermatitis, and approximately 8% - 18% of all infants and children are affected by the disease.
We are continuing to enroll patients in the pivotal Phase 3 studies of AN2728 to treat patients with mild-to-moderate atopic dermatitis. We plan to enroll approximately 750 patients in each of two Phase 3 clinical trials.
Keywords for this news article include: Anacor Pharmaceuticals Inc., Dermatology, Atopic Dermatitis, Investment and Finance.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC